The Spectranetics Corp (SPNC) 24.23 $SPNC
J&J Earnings Beat Estimates As Pharma Sales Shine
at Investor's Business Daily - Tue Apr 15, 10:17AM CDT
Johnson & Johnson (JNJ) kicked off the medical industry's Q1 earnings season with a modest upside surprise Tuesday, sending the stock up 1.5% in morning trading on the stock market today. J&J's earnings, minus one-time items, totaled $1.54 a share,...
Health Care Sector Equities Update -- Research on Endologix, Align Technology, Spectranetics, and Unilife
PR Newswire - Mon Apr 14, 8:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors posted losses. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has declined 2.36% in last three months. Investor-Edge has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Align Technology Inc. (NASDAQ: ALGN), Spectranetics Corp. (NASDAQ: SPNC) and Unilife Corp. (NASDAQ: UNIS). Free technical research on ELGX, ALGN, SPNC and UNIS can be downloaded upon signing up at:
Commit To Buy Spectranetics At $20, Earn 9.6% Annualized Using Options
at The Street - Fri Apr 11, 10:37AM CDT
Investors considering a purchase of Spectranetics Corp. shares, but cautious about paying the going market price of $24.01/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Spectranetics Announces FDA Clearance for Mechanical Lead Extraction Devices
GlobeNewswire - Thu Apr 10, 3:35PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced FDA clearance of two new mechanical lead extraction platforms that expand physicians' options for safe removal of cardiac leads. Each incorporates innovative designs for mechanical extraction aimed at providing total lead management solutions.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 08, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Spectranetics (SPNC) Stock Is Plummeting Today
at The Street - Tue Apr 08, 1:05PM CDT
Spectranetics (SPNC) shares are down -11.6% to $23.08 in trading on Tuesday.
Spectranetics Announces Preliminary Results for First Quarter 2014 and Updates 2014 Guidance
GlobeNewswire - Mon Apr 07, 3:02PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced preliminary results for the three months ended March 31, 2014. The company will provide a full report on the financial results for the first quarter of 2014, and conduct a conference call with investors, on April 23, 2014. Spectranetics expects to report the following results for its first quarter of 2014, all compared with the three months ended March 31, 2013:
Spectranetics Up 77.6% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Tue Apr 01, 9:37AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 6 months, Spectranetics has returned 77.62% as of today's recent price of $30.79.
Spectranetics Announces Early Success of EXCITE ISR; Clinical Trial Demonstrated Safety and Efficacy Superiority
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Enrollment in Study Concluded
Research and Markets: Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
Business Wire - Tue Mar 25, 1:22PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t86twq/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering.
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
Spectranetics Up 69.3% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Tue Mar 25, 9:11AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 6 months, Spectranetics has returned 69.31% as of today's recent price of $29.35.
Shares of SPNC Up 80.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 17, 4:48PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.33. In approximately 6 months, Spectranetics has returned 80.44% as of today's recent price of $31.28.
Post Earnings Update: Spectranetics Has Climbed 8.3% Higher in Past 2 Weeks (SPNC)
Comtex SmarTrend(R) - Mon Mar 17, 7:01AM CDT
18 days ago, on February 27th, 2014, Spectranetics (NASDAQ:SPNC) reported its earnings. Analysts, on average, expected earnings of $0.02 per share on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Shares of Spectranetics have climbed from $28.75 to $31.14, representing a gain of 8.3% since the company reported earnings 18 days ago.
Uptrend Call Working As Spectranetics Stock Rises 75.1% (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 11:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 75.08% as of today's recent price of $30.35.
Post Earnings Update: Spectranetics Has Climbed 7.0% Higher in Past Week (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
A week ago on February 27th, 2014 Spectranetics (NASDAQ:SPNC) reported earnings and analysts, on average, expected earnings of $0.02 on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Since the company's report, shares of Spectranetics have risen from $28.75 to $30.75, representing a gain of 7.0% in the past 11 days.
70.2% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 70.23% as of today's recent price of $29.51.
Spectranetics Achieves Fourth Quarter Revenue of $41.9 Million
GlobeNewswire - Thu Feb 27, 3:14PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the quarter and year ended December 31, 2013. Highlights of the quarter (all compared with the quarter ended December 31, 2012) include:
J&J Earnings Beat Estimates As Pharma Sales Shine
at Investor's Business Daily - Tue Apr 15, 10:17AM CDT
Johnson & Johnson (JNJ) kicked off the medical industry's Q1 earnings season with a modest upside surprise Tuesday, sending the stock up 1.5% in morning trading on the stock market today. J&J's earnings, minus one-time items, totaled $1.54 a share,...
Health Care Sector Equities Update -- Research on Endologix, Align Technology, Spectranetics, and Unilife
PR Newswire - Mon Apr 14, 8:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors posted losses. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has declined 2.36% in last three months. Investor-Edge has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Align Technology Inc. (NASDAQ: ALGN), Spectranetics Corp. (NASDAQ: SPNC) and Unilife Corp. (NASDAQ: UNIS). Free technical research on ELGX, ALGN, SPNC and UNIS can be downloaded upon signing up at:
Commit To Buy Spectranetics At $20, Earn 9.6% Annualized Using Options
at The Street - Fri Apr 11, 10:37AM CDT
Investors considering a purchase of Spectranetics Corp. shares, but cautious about paying the going market price of $24.01/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Spectranetics Announces FDA Clearance for Mechanical Lead Extraction Devices
GlobeNewswire - Thu Apr 10, 3:35PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced FDA clearance of two new mechanical lead extraction platforms that expand physicians' options for safe removal of cardiac leads. Each incorporates innovative designs for mechanical extraction aimed at providing total lead management solutions.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 08, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Spectranetics (SPNC) Stock Is Plummeting Today
at The Street - Tue Apr 08, 1:05PM CDT
Spectranetics (SPNC) shares are down -11.6% to $23.08 in trading on Tuesday.
Spectranetics Announces Preliminary Results for First Quarter 2014 and Updates 2014 Guidance
GlobeNewswire - Mon Apr 07, 3:02PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced preliminary results for the three months ended March 31, 2014. The company will provide a full report on the financial results for the first quarter of 2014, and conduct a conference call with investors, on April 23, 2014. Spectranetics expects to report the following results for its first quarter of 2014, all compared with the three months ended March 31, 2013:
Spectranetics Up 77.6% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Tue Apr 01, 9:37AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 6 months, Spectranetics has returned 77.62% as of today's recent price of $30.79.
Spectranetics Announces Early Success of EXCITE ISR; Clinical Trial Demonstrated Safety and Efficacy Superiority
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Enrollment in Study Concluded
Research and Markets: Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
Business Wire - Tue Mar 25, 1:22PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t86twq/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering.
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
Spectranetics Up 69.3% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Tue Mar 25, 9:11AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 6 months, Spectranetics has returned 69.31% as of today's recent price of $29.35.
Shares of SPNC Up 80.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 17, 4:48PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.33. In approximately 6 months, Spectranetics has returned 80.44% as of today's recent price of $31.28.
Post Earnings Update: Spectranetics Has Climbed 8.3% Higher in Past 2 Weeks (SPNC)
Comtex SmarTrend(R) - Mon Mar 17, 7:01AM CDT
18 days ago, on February 27th, 2014, Spectranetics (NASDAQ:SPNC) reported its earnings. Analysts, on average, expected earnings of $0.02 per share on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Shares of Spectranetics have climbed from $28.75 to $31.14, representing a gain of 8.3% since the company reported earnings 18 days ago.
Uptrend Call Working As Spectranetics Stock Rises 75.1% (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 11:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 75.08% as of today's recent price of $30.35.
Post Earnings Update: Spectranetics Has Climbed 7.0% Higher in Past Week (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
A week ago on February 27th, 2014 Spectranetics (NASDAQ:SPNC) reported earnings and analysts, on average, expected earnings of $0.02 on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Since the company's report, shares of Spectranetics have risen from $28.75 to $30.75, representing a gain of 7.0% in the past 11 days.
70.2% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 70.23% as of today's recent price of $29.51.
Spectranetics Achieves Fourth Quarter Revenue of $41.9 Million
GlobeNewswire - Thu Feb 27, 3:14PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the quarter and year ended December 31, 2013. Highlights of the quarter (all compared with the quarter ended December 31, 2012) include:
